Frizzled-7 Identifies Platinum Tolerant Ovarian Cancer Cells Susceptible to Ferroptosis
Authors:
- Yinu WangYWYinu Wang
- Guangyuan ZhaoGZGuangyuan Zhao
- Salvatore CondelloSCSalvatore Condello
- Hao HuangHHHao Huang
- Horacio CardenasHCHoracio Cardenas
- Edward TannerETEdward Tanner
- Jian-Jun WeiJWJian-Jun Wei
- Yanrong JiYJYanrong Ji
- Junjie LiJLJunjie Li
- Yuying TanYTYuying Tan
- Ramana DavuluriRDRamana Davuluri
- Ji-Xin ChengJCJi-Xin Cheng
Preprint
Abstract
Defining traits of platinum tolerant cancer cells could expose new treatment vulnerabilities. Here, new markers associated with platinum tolerant cells and tumors were identified by using in vitro and in vivo ovarian cancer (OC) models treated repetitively with carboplatin and validated in human specimens. Platinum-tolerant cells and tumors were found to be enriched in ALDH (+) cells, formed more spheroids, and expressed increased levels of stemness-related transcription factors compared to parental cells. Additionally, platinum-tolerant cells and tumors highly expressed the Wnt receptor, Frizzled 7 ( FZD7 ). FZD7 knock down improved sensitivity to platinum, decreased spheroid formation, and delayed tumor initiation. The molecular signature distinguishing FZD7(+) from FZD7(-) cells included epithelial-to-mesenchymal (EMT), stemness , and oxidative phosphorylation enriched gene sets. Overexpression of FZD7 activated the oncogenic factor Tp63 , driving upregulation of glutathione metabolism pathways, including glutathione peroxidase 4 (GPX4), which protects cells from chemotherapy-induced oxidative stress. FZD7(+) platinum-tolerant OC cells were more sensitive and underwent ferroptosis after treatment with GPX4 inhibitors. FZD7, Tp63 and glutathione metabolism gene sets were strongly correlated in the OC Tumor Cancer Genome Atlas (TCGA) database and in human OC specimens residual after chemotherapy. These results support the existence of a platinum-tolerant cell population with partial stem cell features, characterized by FZD7 expression and dependent on FZD7-β-catenin-Tp63-GPX4 pathway for survival. The findings reveal a novel therapeutic vulnerability of platinum tolerant cancer cells and provide new insight into a potential “persister cancer cell” phenotype.Keywords
All Related Versions
- Published version: Cancer Research, 81 (2), 384.
This publication has 46 references indexed in Scilit:
- Intratumoral Heterogeneity: More Than Just MutationsTrends in Cell Biology, 2019
- A Novel ALDH1A1 Inhibitor Targets Cells with Stem Cell Characteristics in Ovarian CancerCancers, 2019
- IL-6 mediates platinum-induced enrichment of ovarian cancer stem cellsJCI Insight, 2018
- Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibitionNature, 2017
- Adaptive Chromatin Remodeling Drives Glioblastoma Stem Cell Plasticity and Drug ToleranceCell Stem Cell, 2017
- Epigenetic Targeting of Ovarian Cancer Stem CellsCancer Research, 2014
- Cancer stem cells: an evolving conceptNature Reviews Cancer, 2012
- Aldehyde Dehydrogenase in Combination with CD133 Defines Angiogenic Ovarian Cancer Stem Cells That Portend Poor Patient SurvivalCancer Research, 2011
- A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell SubpopulationsCell, 2010
- Identification and Characterization of Ovarian Cancer-Initiating Cells from Primary Human TumorsCancer Research, 2008